Document:

Exhibit 10.1

 

CONSULTING AGREEMENT

 

This
Consulting Agreement (“Agreement”), effective as of April 28, 2021 (“Effective Date”)
is entered into by and between Biosecurity Technology, Inc., a Nevada corporation (Formerly known as Axelerex Corp.) (the “Company”),
and Global Food Innovations, LLC (the “Consultant”), a Texas limited liability company.

 

RECITALS

 

WHEREAS,
Company desires to engage the services of Consultant, on a nonexclusive basis, to act as a general business and scientific consultant,
as described further herein, by assisting and advising the Company on the development and enhancement of the Company’s business.

 

NOW THEREFORE, in consideration
of the promises and the mutual covenants and agreements set forth below, the legal sufficiency of which is acknowledged, the parties
covenant and agree as follows:

 

1. Term
of Consultancy. Subject to the terms and conditions set forth herein, Company agrees to retain the Consultant to act as an
independent contractor to the Company, and the Consultant agrees to provide the services described herein to the Company. The term
of this Agreement shall commence on the Effective Date and end on three year anniversary of the Effective Date (the “Initial
Term”), unless terminated earlier as permitted herein. This Agreement shall be automatically renewed at the end of the Initial
Term for successive one-year terms (each, a “Renewal Term”), unless either party hereto gives written notice of its
intention not to renew sixty days (60) before the expiration of the Initial Term or a Renewal Term, as applicable. The Parties
agree that certain terms of this Agreement, including without limitation Section 2 and Section 4 of this Agreement, may be modified
in a Renewal Term, with any such modification or amendment to be agreed to in writing by the Parties. The Initial Term and any
Renewal Terms shall collectively be referred to herein as the “Term”.

 

2. Duties
of Consultant. Consultant agrees that it will provide to the Company the services (the “Services”) set forth in
Schedule A attached hereto.

 

3. Allocation
of Time and Energies; Principals. Consultant and the Company agree that Consultant will perform the Services set forth
herein, together with any and all additional or different tasks that Company and Consultant mutually agree upon during the
term of this Agreement, in a diligent and professional manner and exclusively by Mark Miller, Mindy Brashears, Dale Woerner
and Marcos Sanchez-Plata (each, a “Principal” and collectively, the “Principals”). During the term of
this Agreement, Consultant shall have absolute sole discretion to determine where and when to provide the Services. That is
to say, no specific hours-per-day requirement will be adhered to, and Consultant will determine when to perform the Services
described herein, taking into consideration any and all competing demands on each Principal’s employment by a Tier 1
University System. Notwithstanding the above, and without foregoing same, the parties acknowledge and agree that a
disproportionately large amount of the effort to be expended and the costs to be incurred by the Consultant and the benefits
to be received by the Company are expected to occur within or shortly after the first six months of the Effective Date of
this Agreement, and Consultant will work in good faith to initiate and implement the tasks and Services called for by this
Agreement within the such time frame.

 

     

     

    

 

It is explicitly
understood that Consultant’s performance of its duties hereunder will in no way be measured by the price of the Company’s common
stock, nor the trading volume of the Company’s common stock.

 

4. Remuneration.
In full consideration of Consultant’s performance of the Services, the Company shall pay Consultant as follows:

 

a. Commission
of Gross Sales. Company shall pay to Consultant a commission of five percent (5%) of Gross Revenues for the Company. As used
herein, Gross Revenues means the revenues actually collected from the sale of all products, goods and merchandise sold by Company,
without regard to the type of products, goods, or merchandise sold or the industry to which the sale occurred, that is to say,
revenues collected from all sales to any customer shall be included (regardless of whether such customer is domestic or international),
together with the revenues collected from all services performed by or on behalf of Company (regardless of whether such services
are performed domestically or internationally), including but not limited to any and all services performed by Consultant as an
agent for Company, together with any and all services performed by any other consultants as an agent for the Company for cash,
credit or otherwise, without reserve or deduction for uncollected amounts, and deposits not refunded to customers, less discounts,
promotions, rebates or similar normal and customary concessions. Payment shall be made to Consultant on a quarterly basis, with
payments being due to Consultant no later than March 1, June 1, September 1, and December 1 each year that this Agreement is in
effect. Payment shall be made via wire transfer to an account instructed by Consultant.

 

b. Warrants.
Company shall also cause to be provided to Consultant up to Four Million (4,000,000) Common Stock Warrants (the “Warrants”),
granting Consultant the right to purchase shares of Company’s common stock (“Company Shares”) at a cashless exercise
price of Zero and 25/100s Dollars ($0.25) per Company Share. The issuance of Warrants shall be in accordance with the Warrant Purchase
Agreement attached hereto as Exhibit 4.b.

 

		5.	Termination.

 

a. Consultant,
in its sole discretion, may terminate this Agreement at any time without cause by providing at least thirty (30) days’ prior
notice to the Company. Commencing after the third anniversary of the Effective Date, Company, in its sole discretion, may terminate
this Agreement at any time without cause by providing at least thirty (30) days’ prior notice to the Consultant.

 

b.
Either party may terminate this Agreement, effective upon written notice to the other party (the “Defaulting
Party”), if the Defaulting Party breaches this Agreement and such breach is incapable of cure or, with respect to a
breach capable of cure, the Defaulting Party does not cure such breach within ten (10) days after receipt of written notice
of such breach.

 

    2

     

    

 

		6.	Indemnification.

 

a. Consultant
shall defend, indemnify and hold harmless the Company and its affiliates and each of their officers, directors, employees, agents,
successors and assigns from and against any and all claims, losses, damages, liabilities, actions, costs or expenses of any kind
(including reasonable attorney’s fees) arising out of or resulting from (i) Consultant’s negligence or intentional
misconduct in performing the Services, (ii) Consultant’s breach of any representation, warranty or covenant contained in
this Agreement, and (iii) Consultant’s breach of any applicable law in performing the Services.

 

b. Company
shall defend, indemnify and hold harmless the Consultant and its officers, directors, employees, agents, successors and assigns
from and against any and all claims, losses, damages, liabilities, actions, costs or expenses of any kind (including reasonable
attorney’s fees) arising out of or resulting from Company’s breach of any representation, warranty or covenant contained
in this Agreement.

 

		7.	Representations. Consultant represents and warrants to Company that:

 

a. it
has the full right, power, and authority to enter into this Agreement and to perform its obligations hereunder.

 

b. when
executed and delivered by Consultant, this Agreement will constitute the legal, valid, and binding obligation of Consultant, enforceable
against such party in accordance with its terms.

 

c. it
shall perform the Services using personnel of required skill, experience, and qualifications and in a professional and workmanlike
manner in accordance with generally recognized industry standards for similar services and shall devote adequate resources to meet
its obligations under this Agreement.

 

d. it
is in compliance with, and shall perform the Services in compliance with, all applicable laws.

 

e. it
is not required to maintain any licenses and registrations under federal or state law in order to perform the Services set forth
herein.

 

f. to
the best of its knowledge, Consultant and its Principals are not the subject of any investigation, claim, decree or judgment involving
any violation of the SEC or securities laws.

 

g. it
is not a securities Broker Dealer or a registered investment advisor.

 

h. to
the best of its knowledge, Consultant has not violated any rule or provision of any regulatory agency having jurisdiction over
the Company.

 

    3

     

    

 

8. Legal
Representation. The Company acknowledges that it has been represented by independent legal counsel in the preparation of
this Agreement. Consultant represents that it has consulted with independent legal counsel and/or tax, financial and business
advisors, to the extent the Consultant deemed necessary.

 

		9.	Confidential Information and Intellectual Property.

 

 a. Consultant agrees:

 

i. not
to disclose or otherwise make available Confidential Information to any third party without the prior written consent of the Company;
provided, however, that Consultant may disclose Confidential Information to its officers, employees, consultants, and legal advisors
who have a “need to know”, who have been apprised of this restriction, and who are themselves bound by nondisclosure
obligations at least as restrictive as those set forth in this Section;

 

ii. to
use the Confidential Information only for the purposes of performing its obligations under the Agreement; and

 

iii. to
promptly notify the Company in the event it becomes aware of any loss or disclosure of any of the Confidential Information.

 

b. If
Consultant becomes legally compelled to disclose any Confidential Information, the Consultant shall provide prompt written notice
of such requirement so that the Company may seek, at its sole cost and expense, a protective order or other remedy and reasonable
assistance in opposing such disclosure or seeking a protective order or other limitations on disclosure. If, after providing such
notice and assistance as required herein, the Consultant remains required by applicable law to disclose any Confidential Information,
the Consultant shall disclose no more than that portion of the Confidential Information which, on the advice of the Consultant’s
legal counsel, the Consultant is legally required to disclose.

 

c. For
purposes of this Agreement, “Confidential Information” shall mean any information that is treated as confidential by
Company, including but not limited to all non-public information about its business affairs, products or services, intellectual
property rights, trade secrets, third-party confidential information, and other sensitive or proprietary information, whether disclosed
orally or in written, electronic, or other form or media, and whether or not marked, designated, or otherwise identified as “confidential”.
Confidential Information shall not include information that: (a) is or becomes generally known by the public other than by breach
of this Agreement by, or other wrongful act of, the Consultant; (b) is developed by the Consultant independently of, and without
reference to, any Confidential Information; or (c) is received by the Consultant from a third party who is not under any obligation
to the Company to maintain the confidentiality of such information.

 

    4

     

    

 

 d. Intellectual Property.

 

i. All
intellectual property rights, including copyrights, patents, patent disclosures and inventions (whether patentable or not),
trademarks, service marks, trade secrets, know-how, and other confidential information, trade dress, trade names, logos,
corporate names and domain names, together with all of the goodwill associated therewith, derivative works and all other
rights (collectively, “Intellectual Property Rights”) in and to all documents, work product and other materials
that are delivered to Company under this Agreement or prepared by or on behalf of Consultant in the course of performing the
Services (collectively, the “Deliverables”) shall be owned exclusively by Company. Consultant agrees, and shall
cause its Principal and other employees and agents (collectively, “Consultant Personnel”) to agree, that with
respect to any Deliverables that may qualify as “work made for hire” as defined in 17 U.S.C. § 101, such
Deliverables are hereby deemed a “work made for hire” for Company. To the extent that any of the Deliverables do
not constitute a “work made for hire,” Consultant hereby irrevocably assigns, and shall cause the Consultant
Personnel to irrevocably assign to Company, in each case without additional consideration, all right, title, and interest
throughout the world in and to the Deliverables, including all Intellectual Property Rights therein. Consultant shall cause
Consultant Personnel to irrevocably waive, to the extent permitted by applicable law, any and all claims such Consultant
Personnel may now or hereafter have in any jurisdiction to so-called “moral rights” or rights of droit moral with
respect to the Deliverables.

 

ii. Consultant
grants, and shall cause the Consultant Personnel to grant, to Company a perpetual, fully paid-up, royalty-free, worldwide license
to use, perform, display, execute, reproduce, distribute, modify, make, sell, offer to sell and otherwise exploit all Intellectual
Property Rights in and to all documents, work product and other materials that are prepared by or created by Consultant in the
course of performing the testing and related research of Company’s products and services for third parties, including clients
and prospective clients of Company.

 

e. Feedback.
If Consultant or any Consultant Personnel sends or transmits any communications or materials to Company by mail, email, telephone,
or otherwise, suggesting or recommending changes to Company products and/or services, including without limitation, new features
or functionality relating thereto, or any comments, questions, suggestions, or the like (collectively, “Feedback”), Company
is free to use such Feedback irrespective of any other obligation or limitation between the parties governing such Feedback. Consultant
hereby assigns, and shall cause the Consultant Personnel to irrevocably assign to Company, all right, title, and interest in, and
Company is free to use, without any attribution or compensation to any party, any ideas, know-how, concepts, techniques, or other
intellectual property rights contained in the Feedback, for any purpose whatsoever, although Company is not required to use any
Feedback

 

f. Survival.
The obligations in this Section 9 shall survive the termination of this Agreement.

 

    5

     

    

 

10. Status
as Independent Contractor. Consultant’s engagement pursuant to this Agreement shall be as independent contractor, and not
as an employee, officer or other agent of the Company. Neither party to this Agreement shall represent or hold itself out to
be the employer or employee of the other. Consultant further acknowledges the consideration provided hereinabove is a gross
amount of consideration and that the Company will not withhold from such consideration any amounts as to income taxes, social
security payments or any other payroll taxes. All such income taxes and other such payment shall be made or provided for by
Consultant and the Company shall have no responsibility or duties regarding such matters. Neither the Company nor the
Consultant possesses the authority to bind each other in any agreements without the express written consent of the entity to
be bound.

 

11. Reimbursement
of Expenses. The Company shall reimburse the Consultant for all reasonable travel and research expenses incurred or paid by
the Consultant in connection with, or related to, the performance of the Services; provided, in regards to any travel expense,
as a condition to the Company reimbursing the Consultant for such expense, the Consultant must receive written approval from the
Company as to such expense prior to incurring or paying such expense; provided, further, in regards to any research expense, as
a condition to the Company reimbursing the Consultant for such expense, the Consultant must submit to, and receive written approval
from, the Company, on a per project basis, a detailed budget, which shall set forth all expenses estimated to be incurred in connection
with the completion of such project, prior to incurring or paying such expense. Consultant shall account to the Company in writing
for all expenses for which reimbursement is sought and shall supply to the Company copies of all relevant invoices, receipts or
other evidence reasonably requested by the Company.

 

12.
Consultant’s Members are University Professors. As of the Effective Date of this Agreement, the Principals are all
employed by Texas Tech University, a Tier 1 University located in Lubbock, Texas, as professors in the College of Agricultural
Sciences and Natural Resources – Department of Animal Science. In the event that any of the Principal’s become employed
by another institution during the term of this Agreement, and that affected Principal remains as a member or manager of Consultant
and continues to be able to provide Services consistent with prior practices, this Agreement shall remain in full force and effect.

 

Understanding
that all of the Principals must abide by University policy and other employer-imposed regulations and restrictions, and recognizing
that each Principal is a renowned scientist in his or her respective field, Company agrees that it shall present to Consultant
any Company written materials, including any and all advertisements, sales pitches, research results, marketing materials, and
the like, which refer to the name or likeness of any of the Principals or which specifically refers to the research conducted by
or in cooperation with any of the Principals, whether such research was conducted on behalf of Company or not, prior to issuance
or delivery to a third party for Consultant’s review and approval, such approval not to be unreasonably withheld, conditioned
or delayed. Failure to comply with this term shall be deemed a material breach of this Agreement.

 

    6

     

    

 

13. Notices.
All notices, requests, and other communications hereunder shall be deemed to be duly given if sent by U.S. mail, postage prepaid,
addressed to the other party at the address as set forth herein below:

 

To the Company:

Biosecurity Technology, Inc

3821 S. 148th Street

Omaha, NE 68130

Attn: Dan Lynn

 

With a copy to:

Dvorak Law Group, LLC

9500 W. Dodge Rd., Ste. 100

Omaha, NE 68114

Attn: David R. Mayer

 

To the Consultant:

 

Global Food Innovations, LLC

1762 FM 2060

Abernathy, TX 79311

Attn: Mark Miller

 

Either party
may change the address to which notices for it shall be addressed by providing notice of such change to the other party in the
manner set forth in this Section 13.

 

14. Choice
of Law, Jurisdiction and Venue. This Agreement shall be governed by, construed and enforced in accordance with the laws of
the State of Nebraska without giving effect to any conflict of laws principles that would cause the laws of any other jurisdiction
to apply. The parties agree that the state or federal courts located in Douglas County, Nebraska shall have exclusive venue of
any dispute and will have jurisdiction over all parties.

 

15. Assignment;
Successors and Assigns. Consultant may not assign, transfer, or delegate any of its rights or obligations under this Agreement
without the prior written consent of the Company. This Agreement is binding upon and shall insure to the benefit of the parties’
successors and permitted assigns.

 

16. Complete
Agreement. This Agreement contains the entire agreement of the parties relating to the subject matter of this Agreement. This
Agreement and its terms may not be changed orally but only by an agreement in writing signed by the party against whom enforcement
of any waiver, change, modification, extension or discharge is sought.

 

17. Counterparts.
This Agreement may be executed in multiple counterparts and by electronic signature, each of which shall be deemed an original
and all of which together shall constitute one instrument.

 

18. Severability.
If any term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality,
or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term
or provision in any other jurisdiction.

 

[REMAINDER OF PAGE
LEFT INTENTIONALLY BLANK; SIGNATURE PAGE TO FOLLOW.]

    7

     

    

 

IN WITNESS WHEREOF, the parties
have executed this Consulting Agreement as of the Effective Date.

 

“Company”:Biosecurity Technology, Inc.

 

	By:	/s/ Dan
    Lynn	 
	 	Dan Lynn	 
	 	Its: CEO	 

  

“Consultant”:Global Food Innovations,
LLC

 

	By: 	/s/ Mark
    Miller	 
	 	Mark Miller	 
	 	Its: Manager	 

 

 

Consulting Agreement

Signature Page

 

     

     

    

Schedule A

 

Services

 

(a) Introduce
the Company to potential new clients (whether domestically or internationally), with an emphasis to be on potential new clients
in the livestock and food industries, but in no way should Consultant’s ability to introduce the Company to potential new
clients in other industries deem to be limited by the foregoing, and Consultant shall use good faith efforts to identify potential
new clients across industries during the term of this Agreement;

 

(b) Research
and identify potential application of Company’s goods and services with potential new clients and business partners, including,
where applicable and necessary, the conducting of scientific research projects involving Company’s goods and services and
potential new clients and business partners;

 

(c) Conduct
meetings, in person or by telephone with potential new clients and business partners, in furtherance of the duties and services
described herein in order to further the Company’s plans, goals and activities;

 

(d) At
the Company’s request, review business plans, strategies, mission statements, research proposals, budgets, proposed transactions
or other plans;

 

(e) At
the Company’s request, and following Company’s submitting agreed upon payment to Consultant for the costs and expenses
associated with performing same, perform or have performed certain research projects investigating the viability of Company’s
products or services in certain industries or applications;

 

(f) Provide
input to Company’s marketing and sales plans concerning new goods, programs, or services could impact or serve the livestock
or food sector; and

 

(g) Perform
other tasks which contribute to the Company’s efforts to expand its footprint and product offerings in the livestock and
food sector, together with the Company’s efforts to expand its footprint in any and all other industries in which its products
may already be used or may be introduced in the future as a viable solution, with the number and types of tasks to be performed
to be subject to Consultant’s sole discretion.

 

Consulting Agreement

Schedule A

     

     

    

 

Exhibit 4.b

 

Purchase
Warrant Agreement

 

(See attached)

 

Consulting Agreement

Exhibit 4.b

 

     

     

    

THE WARRANTS AND THE SECURITIES
ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR QUALIFIED
UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED
OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SECURITIES IS EFFECTIVE UNDER THE ACT AND IS QUALIFIED UNDER APPLICABLE
STATE AND FOREIGN LAW OR (II) THE TRANSACTION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS UNDER THE ACT
AND THE QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE AND FOREIGN LAW AND, IF THE COMPANY REQUESTS, AN OPINION SATISFACTORY
TO THE COMPANY TO SUCH EFFECT HAS BEEN RENDERED BY COUNSEL.

 

PURCHASE WARRANT AGREEMENT

 

This Purchase
Warrant Agreement (this “Agreement”), effective as of April 28, 2021 (the “Effective Date”),
is entered into by and between Biosecurity Technology, Inc., a Nevada corporation (formerly known as Axelerex Corp.) (the “Company”),
and Global Food Innovations, LLC, a Texas limited liability company (the “Holder”).

 

RECITALS

 

WHEREAS,
Company and Holder are entering into that certain Consulting Agreement, dated of even date herewith (the “Consulting Agreement”),
pursuant to which Holder has agreed to perform certain Services (as defined in the Consulting Agreement) for Company;

 

WHEREAS,
in partial consideration of Holder’s performance of Services, Company desires to issue to Holder the Warrants (as defined
below), subject to the terms and conditions of this Agreement.

 

NOW THEREFORE,
in consideration of the promises and the mutual covenants and agreements set forth below, the legal sufficiency of which is acknowledged,
the parties covenant and agree as follows:

 

1. Definitions.
As used in this Agreement, the following terms have the respective meanings set forth below:

 

“Aggregate
Exercise Price” means an amount equal to the product of (a) the number of Warrant Shares in respect of which such Warrant
is then being exercised pursuant to Section 4 hereof, multiplied by (b) the Exercise Price.

 

“Board” means
the board of directors of the Company.

 

“Business
Day” means any day, except a Saturday, Sunday or legal holiday, on which banking institutions in the city of Omaha, Nebraska
are authorized or obligated by law or executive order to close.

 

“Common
Stock” means (i) the common stock, of the Company, $0.001 par value per share, as authorized as of the date hereof and
(ii) any capital stock into which the securities described in subsection (i) shall have been converted, exchanged or reclassified
following the date hereof.

 

     

     

    

“Exercise
Date” means, for any given exercise of each Warrant, the date on which the conditions to such exercise as set forth in
Section 4 shall have been satisfied at or prior to 5:00 p.m. (Central) on a Business Day, including, without limitation, the receipt
by the Company of the Notice of Exercise.

 

“Fair
Market Value” means, if the Company’s Common Stock is then traded or quoted on a nationally recognized securities
exchange, inter-dealer quotation system or over-the- counter market (a “Trading Market”), the fair market value
of a share of Common Stock shall be the closing price or last sale price of a share of the Common Stock reported for the Business
Day immediately before the date on which Holder delivers its Notice of Exercise to the Company. If the Company’s Common Stock
is not traded in a Trading Market, the Board of the Company shall determine the fair market value of a share of Common Stock in
its reasonable good faith judgment.

 

“Person”
means any individual, sole proprietorship, partnership, limited liability company, corporation, joint venture, trust, incorporated
organization or government or department or agency thereof.

 

“Warrant
Shares” means the shares of Common Stock of the Company then purchasable upon exercise of each Warrant in accordance
with the terms of this Agreement.

 

		2.	Warrants. The Company hereby agrees to issue the following warrants to Holder:

 

(a) The
Company shall issue, on the Effective Date, a warrant (the “Initial Warrant”) to Holder which certifies that
Holder is entitled to purchase from the Company One Million (1,000,000) duly authorized, validly issued, fully paid and nonassessable
shares of Common Stock at a purchase price per share of Zero and 25/100 Dollars ($0.25) (the “Exercise Price”),
subject to the terms and conditions of this Agreement.

 

(b) Provided
the Consulting Agreement is still in force and effect and subject to the terms and conditions of this Agreement, the Company shall
issue, on each anniversary of the Effective Date for three (3) consecutive years, an additional warrant (each, an “Additional
Warrant”, and along with the Initial Warrant, each a “Warrant” and collectively the “Warrants”)
to Holder which certifies that Holder is entitled to purchase from the Company Additional Shares of Common Stock that are duly
authorized, validly issued, fully paid and nonassessable at a purchase price per share of the Exercise Price. For purpose of this
Agreement, “Additional Shares” means an amount of shares equal to the product of (i) Two Hundred and Fifty Thousand
(250,000) multiplied by (ii) (x) the number of Principals (as defined in the Consulting Agreement) performing Services on behalf
of the Consultant in a meaningful manner in the reasonable discretion of Company as of such anniversary plus (y) the number of
Principals not performing Services on behalf of the Consultant due to death or being deemed Disabled as of such anniversary. Notwithstanding
anything herein to the contrary, the maximum amount of Additional Shares per Additional Warrant shall be One Million (1,000,000)
shares. By way of example, if, on the third (3rd) anniversary of the Effective Date, two (2)
Principals are performing Services on behalf of the Consultant and one (1) Principal is not performing Services on behalf of the
Consultant due to either being deemed Disabled or having died, the Additional Warrant issued by the Company to Holder shall be
for Seven Hundred Fifty Thousand (750,000) shares of Common Stock.

 

    2

     

    

 

(c) For
purposes of this Agreement, “Disabled” means, in regards to a Principal, physically and/or mentally unable
to perform all or substantially all of such Principal’s usual and customary duties as a Principal under the Consulting
Agreement currently and for the foreseeable future and such inability has continued for at least six (6) consecutive months.
The determination of whether a Principal is “Disabled” under the foregoing definition shall be made by one or
more physicians selected for that purpose by the Company.

 

3. Term
of Warrant. Subject to the terms and conditions hereof, at any time or from time to time after each respective Warrant is issued
and prior to 5:00 p.m. (Central) on the seventh (7th) anniversary of the Effective Date or,
if such day is not a Business Day, on the next preceding Business Day (the “Exercise Period”), the Holder may
exercise each Warrant for all but not less than all of the Warrant Shares purchasable thereunder (subject to adjustment as provided
herein).

 

 4. Exercise of Warrant.

 

(a) Exercise
Procedure. Each Warrant may be exercised by the Holder delivering the Company a duly executed Notice of Exercise form, attached
hereto as Exhibit A (the “Notice of Exercise”), from time to time on any Business Day during the Exercise
Period, for all but not less than all of the Warrant Shares purchasable thereunder, and payment to the Company of the Aggregate
Exercise Price in accordance with Section 4(b).

 

(b) Payment
of the Aggregate Exercise Price. Payment of the Aggregate Exercise Price shall be made by instructing the Company to issue
Warrant Shares then issuable upon exercise of each Warrant on a net basis such that, without payment of any cash consideration
or other immediately available funds, the Holder shall surrender each Warrant in exchange for the number of Warrant Shares as is
computed using the following formula:

 

X = Y(A - B) ÷ A

 

Where:

 

X = the number of Warrant Shares to be issued to the
Holder.

 

Y = the total number of Warrant
Shares purchasable under such Warrant.

 

A = the Fair Market Value of one
Warrant Share as of the applicable Exercise Date. B = the Exercise Price.

 

(c) Fractional
Shares. The Company shall not issue a fractional Warrant Share upon exercise of any Warrant. In the event of withholding of
Warrant Shares where the number of shares whose value is equal to the Aggregate Exercise Price is not a whole number, the number
of shares withheld by the Company shall be rounded up to the nearest whole share and the Company shall make a cash payment to the
Holder (by delivery of a certified or official bank check or by wire transfer of immediately available funds) based on the incremental
fraction of a share being so withheld by the Company in an amount equal to the product of (i) such incremental fraction of a share
being so withheld multiplied by (ii) the Fair Market Value per Warrant Share as of the Exercise Date.

 

    3

     

    

 

(d) Delivery
of Stock Certificates. Within a reasonable time after each Warrant is exercised hereunder, the Company shall execute (or
cause to be executed) and deliver (or cause to be delivered) to the Holder a certificate or certificates representing the
Warrant Shares issued upon such exercise, together with cash in lieu of any fraction of a share, as provided in Section 4(c).
The stock certificate or certificates so delivered shall be, to the extent possible, in such denomination or denominations as
the exercising Holder shall reasonably request in the Notice of Exercise and shall be registered in the name of the Holder
or, subject to compliance with Section 6 below, such other Person’s name as shall be designated in the Notice of
Exercise. Each Warrant shall be deemed to have been exercised and such certificate or certificates of Warrant Shares shall be
deemed to have been issued, and the Holder or any other Person so designated to be named therein shall be deemed to have
become a holder of record of such Warrant Shares for all purposes, as of the Exercise Date.

 

(e) Company’s
Representations and Covenants. The Company hereby represents, covenants and agrees:

 

 (i) Each Warrant is, upon issuance, duly authorized and validly issued.

 

(ii) All
Warrant Shares issuable upon the exercise of each Warrant pursuant to the terms hereof shall be, upon issuance, and the Company
shall take all such actions as may be reasonably necessary or appropriate in order that such Warrant Shares are, validly issued,
fully paid and non-assessable, free and clear of all taxes, liens and charges except for restrictions imposed by applicable federal
and state securities laws.

 

(iii) The
Company shall take commercially reasonable actions to help cause the Warrant Shares to be issued without violation by the Company
of any applicable law or governmental regulation or any requirements of any domestic securities exchange upon which shares of Common
Stock or other securities constituting Warrant Shares may be listed at the time of such exercise.

 

(iv) The
Company shall pay all expenses in connection with, and all taxes and other governmental charges that may be imposed with respect
to, the issuance or delivery of Warrant Shares upon exercise of each Warrant; provided, that the Company shall not be required
to pay any tax or governmental charge that may be imposed with respect to any applicable withholding or the issuance or delivery
of the Warrant Shares to any Person other than the Holder, and no such issuance or delivery shall be made unless and until the
Person requesting such issuance has paid to the Company the amount of any such tax, or has established to the satisfaction of the
Company that such tax has been paid.

 

(f) Conditional
Exercise. Notwithstanding any other provision hereof and subject to the Exercise Period, if an exercise of any Warrant is to
be made in connection with a public offering or a sale of the Company (pursuant to a merger, sale of stock, or otherwise), such
exercise may at the election of the Holder be conditioned upon the consummation of such transaction, in which case such exercise
shall not be deemed to be effective until immediately prior to the consummation of such transaction.

 

(g) Reservation
of Shares. During the Exercise Period, the Company shall at all times reserve and keep available out of its authorized
but unissued Common Stock or other securities constituting Warrant Shares, solely for the purpose of issuance upon the
exercise of the Warrants, the maximum number of Warrant Shares issuable upon the exercise of the Warrants, and the par value
per Warrant Share shall at all times be less than or equal to the applicable Exercise Price. The Company shall not increase
the par value of any Warrant Shares receivable upon the exercise of any Warrant above the Exercise Price then in effect, and
shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully
paid and nonassessable shares of Common Stock upon the exercise of this Warrant.

 

    4

     

    

 

		5.	Adjustment to Number of Warrant Shares.

 

(a) Stock
Dividends and Split-Ups. If after the Effective Date, and subject to the provisions of Section 5(c), the number of outstanding
shares of Common Stock is increased by a stock dividend payable in shares of Common Stock, or by a split-up of shares of Common
Stock, or other similar event, then, on the effective date of such stock dividend, split-up or similar event, the number of shares
of Common Stock issuable upon exercise of each Warrant shall be increased in proportion to such increase in outstanding shares
of Common Stock upon the Holder’s delivery of the Notice of Exercise.

 

(b) Aggregation
of Shares. If after the Effective Date, and subject to the provisions of Section 5(c), the number of outstanding shares of
Common Stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of Common Stock or
other similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar
event, the number of shares of Common Stock issuable upon exercise of each Warrant shall be decreased in proportion to such decrease
in outstanding shares of Common Stock upon the Holder’s delivery of the Notice of Exercise.

 

(c) Adjustments
in Exercise Price. Whenever the number of shares of Common Stock purchasable upon the exercise of the Warrants is adjusted,
as provided in Sections 6.1(a) and (b), the Exercise Price shall be adjusted (to the nearest cent) by multiplying such Exercise
Price immediately prior to such adjustment by a fraction (i) the numerator of which shall be the number of shares of Common Stock
purchasable upon the exercise of the Warrant immediately prior to such adjustment, and (ii) the denominator of which shall be the
number of shares of Common Stock so purchasable immediately thereafter.

 

(d) Reorganization,
Reclassification, Consolidation or Merger. In the event of any (i) capital reorganization of the Company, (ii)
reclassification of the stock of the Company (other than a change in par value or as a result of a stock dividend or
split-up, aggregation or combination of shares), (iii) consolidation or merger of the Company with or into another Person,
(iv) sale of all or substantially all of the Company’s assets to another Person or (v) other similar transaction (other
than any such transaction covered by Sections 6.1(a) and (b)), in each case which entitles the holders of Common Stock to
receive (either directly or upon subsequent liquidation) stock, securities or assets with respect to or in exchange for
Common Stock, each Warrant shall, immediately after such reorganization, reclassification, consolidation, merger, sale or
similar transaction, remain outstanding and shall thereafter, in lieu of or in addition to (as the case may be) the number of
Warrant Shares then exercisable under each Warrant, be exercisable for the kind and number of shares of stock or other
securities or assets of the Company or of the successor Person resulting from such transaction to which the Holder would have
been entitled upon such reorganization, reclassification, consolidation, merger, sale or similar transaction if the Holder
had exercised such Warrant immediately prior to the time of such reorganization, reclassification, consolidation, merger,
sale or similar transaction and acquired the applicable number of Warrant Shares then issuable hereunder as a result of such
exercise (without taking into account any limitations or restrictions on the exercisability of this Warrant); and, in such
case, appropriate adjustment shall be made with respect to the Holder’s rights under this Agreement to insure that the
provisions of this Section 5 shall thereafter be applicable, as nearly as possible, to each Warrant in relation to any shares
of stock, securities or assets thereafter acquirable upon exercise of such Warrant. The provisions of this Section 5(d) shall
similarly apply to successive reorganizations, reclassifications, consolidations, mergers, sales or similar transactions.

 

    5

     

    

 

(e) Notice
of Adjustment. As promptly as reasonably practicable following any adjustment of the number of Warrant Shares pursuant to the
provisions of this Section 5, the Company shall furnish to the Holder notice setting forth in reasonable detail such adjustment
and the facts upon which it is based.

 

(f) Notice
of Corporate Events. If the Company (i) declares a dividend or any other distribution of cash, securities or other property
in respect of its Common Stock, (ii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company,
or (iii) authorizes any capital reorganization of the Company, any reclassification of the Common Stock of the Company, any consolidation
or merger of the Company with or into another Person, or sale of all or substantially all of the Company’s assets to another
Person, then the Company shall deliver to each Holder a notice describing the material terms and conditions of such dividend or
transaction. Notwithstanding anything to the contrary in this Section 5(f), the failure to deliver any notice under this
Section 5(f) or any defect therein shall not affect the validity of the corporate action required to be described in such
notice.

 

		6.	Registration and Transfer.

 

(a) Registration.
Each Warrant shall be issued in registered form only. The Company shall maintain books and records (the “Records”)
for the registration of original issuance, the adjustments contemplated herein, the transfer of any Warrant and any other information
relevant to the terms and conditions of this Agreement. The Company may deem and treat the Person in whose name the Warrant is
registered on such register as the Holder thereof for all purposes, and the Company shall not be affected by any notice to the
contrary, except any transfer of the Warrant effected in accordance with the provisions of this Agreement.

 

(b) Transfer
of Warrant. Subject to the provisions of this Agreement and compliance with applicable securities laws, each Warrant and all
rights hereunder are transferable, in whole or in part, by the Holder without charge to the Holder, upon (i) delivery of written
notice to the Company stating the name, address and taxpayer identification number, the Warrant being transferred and such other
information describing the transfer (including that the transferee has agreed to be bound by the terms and conditions of this Agreement),
together with funds sufficient to pay any transfer taxes incurred with the making of such transfer and (ii) delivery of an opinion
of counsel reasonably satisfactory to the Company that the transfer of the Warrant will be in compliance with applicable securities
laws. Upon such delivery, Company shall update the Records to reflect the transferee as holder of the transferred Warrant.

 

7. Holder
Not Deemed a Stockholder; Limitations on Liability. Except as otherwise specifically provided herein (including Section
5(f)), prior to the issuance to the Holder of the Warrant Shares to which the Holder is then entitled to receive upon the due
exercise of each Warrant, the Holder shall not be entitled to vote or receive dividends or be deemed the holder of shares of
capital stock of the Company for any purpose, nor shall anything contained in this Agreement be construed to confer upon the
Holder, as such, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any
corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or
otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise. In addition, nothing
contained in this Agreement shall be construed as imposing any liabilities on the Holder to purchase any securities (upon
exercise of each Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the
Company or by creditors of the Company.

 

    6

     

    

 

8. Representations
of the Holder. The Holder hereby represents and warrants to the Company as follows:

 

(a) The
Holder is an “accredited investor” as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933,
as amended (the “Securities Act”). The Holder is acquiring each Warrant and the Warrant Shares to be issued
upon exercise thereof for investment for its own account and not with a view towards, or for resale in connection with, the public
sale or distribution of any Warrant or the Warrant Shares, except pursuant to sales registered or exempted under the Securities
Act.

 

(b) The
Holder understands and acknowledges that each Warrant and the Warrant Shares to be issued upon exercise thereof are “restricted
securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving
a public offering and that, under such laws and applicable regulations, such securities may be resold without registration under
the Securities Act only in certain limited circumstances. In addition, the Holder represents that it is familiar with Rule 144
under the Securities Act, as presently in effect, and understands the resale limitations imposed thereby and by the Securities
Act.

 

(c) The
Holder acknowledges that it can bear the economic and financial risk of its investment for an indefinite period, and has such knowledge
and experience in financial or business matters that it is capable of evaluating the merits and risks of each Warrant and the Warrant
Shares to be issued upon exercise thereof. The Holder has had an opportunity to ask questions and receive answers from the Company
regarding the business, properties, prospects and financial condition of the Company.

 

9. Notices.
All notices, requests, and other communications hereunder shall be deemed to be duly given if sent by U.S. mail, postage prepaid,
addressed to the other party at the address as set forth herein below:

 

To the Company:

 

Biosecurity Technology, Inc.

3821 S. 148th
Street

Omaha, NE 68130

Attn: Dan Lynn

 

With a copy to:

 

Dvorak Law Group, LLC

9500 W. Dodge Rd., Ste. 100

Omaha, NE 68114

Attn: David R. Mayer

 

To the Consultant:

 

Global Food Innovations, LLC

1762 FM 2060

Abernathy, TX 79311

Attn: Mark Miller

 

Either party may change the address
to which notices for it shall be addressed by providing notice of such change to the other party in the manner set forth in this
Section.

 

    7

     

    

 

10. Entire
Agreement. This Agreement constitutes the sole and entire agreement of the parties to this Agreement with respect to the subject
matter contained herein, and supersedes all prior and contemporaneous understandings and agreements, both written and oral, with
respect to such subject matter.

 

11. Successors
and Assigns; No Third-Party Beneficiaries. This Agreement is for the sole benefit of and binding upon the Company and the Holder
and their respective successors and, in the case of the Holder, permitted assigns and nothing herein, express or implied, is intended
to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever, under or by
reason of this Agreement.

 

12. Headings.
The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.

 

13. Amendment
and Modification; Waiver. Except as otherwise provided herein, this Agreement may only be amended, modified or supplemented
by an agreement in writing signed by each party hereto. No waiver by the Company or the Holder of any of the provisions hereof
shall be effective unless explicitly set forth in writing and signed by the party so waiving. No waiver by any party shall operate
or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether
of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising,
any rights, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall
any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof
or the exercise of any other right, remedy, power or privilege.

 

14. Severability.
If any term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality,
or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term
or provision in any other jurisdiction.

 

15. Choice
of Law, Jurisdiction and Venue. This Agreement shall be governed by, construed and enforced in accordance with the laws of
the State of Nebraska without giving effect to any conflict of laws principles that would cause the laws of any other jurisdiction
to apply. The parties agree that the state or federal courts located in Douglas County, Nebraska shall have exclusive venue of
any dispute and will have jurisdiction over all parties.

 

16. Counterparts.
This Agreement may be executed in multiple counterparts and by electronic signature, each of which shall be deemed an original
and all of which together shall constitute one instrument.

 

[Rest of Page Intentionally
Left Blank; Signature Page Follows.]

    8

     

    

 

IN WITNESS WHEREOF, the parties
have executed this Agreement as of the Effective Date.

 

	 	COMPANY:
	 	 
	 	Biosecurity Technology, Inc.
	 	 
	 	By:	                            
	 	Name: Dan Lynn
	 	Title: CEO 
	 	 
	 	HOLDER:
	 	 
	 	Global Food Innovations, LLC
	 	 
	 	By:	 
	 	Name: Mark Miller
	 	Title: Manager

 

Purchase Warrant Agreement

Signature Page

 

     

     

    

EXHIBIT A

 

Notice of Exercise

 

Exercise Date:                                                    

To: Biosecurity Technology,
Inc.

 

The undersigned, subject to the
provisions set forth in that certain Purchase Warrant Agreement, dated April 28, 2021 (the “Agreement”), hereby
irrevocably elects to purchase the number of shares of Common Stock of Biosecurity Technology, Inc., a Nevada corporation (the
“Company”), subject to the applicable Warrant, each as set forth below. The undersigned hereby agrees to pay
the Aggregate Exercise Price for such shares of Common Stock in accordance with the terms and conditions of the Agreement. The
undersigned reaffirms the representations and warranties set forth in Section 8 of the Agreement. Capitalized terms used herein
and not otherwise defined shall have the meaning ascribed to them in the Agreement.

 

Date of Issuance of Warrant:                                              

 

Number of Shares of Common Stock:                                         

 

The undersigned requests that certificates for the shares
of Common Stock be issued in the name of:

 

	Name:	 	 
	Address:	 	 
	SSN / Tax ID:	                         	 
	Number of Shares:	 	 

  

	 	HOLDER:
	 	 	 
	 	 	 
	 	 	 
	 	By:	                                   
	 	Name:	 
	 	Title:Exhibit
10.2

 

THE
WARRANTS AND THE SECURITIES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED
OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SECURITIES IS EFFECTIVE UNDER THE ACT AND IS QUALIFIED UNDER APPLICABLE
STATE AND FOREIGN LAW OR (II) THE TRANSACTION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS UNDER THE ACT AND
THE QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE AND FOREIGN LAW AND, IF THE COMPANY REQUESTS, AN OPINION SATISFACTORY TO THE COMPANY
TO SUCH EFFECT HAS BEEN RENDERED BY COUNSEL.

 

PURCHASE
WARRANT AGREEMENT

 

This
Purchase Warrant Agreement (this “Agreement”), effective as of April 28, 2021 (the “Effective Date”),
is entered into by and between Biosecurity Technology, Inc., a Nevada corporation (formerly known as Axelerex Corp.) (the “Company”),
and Global Food Innovations, LLC, a Texas limited liability company (the “Holder”).

 

RECITALS

 

WHEREAS,
Company and Holder are entering into that certain Consulting Agreement, dated of even date herewith (the “Consulting Agreement”),
pursuant to which Holder has agreed to perform certain Services (as defined in the Consulting Agreement) for Company;

 

WHEREAS,
in partial consideration of Holder’s performance of Services, Company desires to issue to Holder the Warrants (as defined below),
subject to the terms and conditions of this Agreement.

 

NOW
THEREFORE, in consideration of the promises and the mutual covenants and agreements set forth below, the legal sufficiency of which
is acknowledged, the parties covenant and agree as follows:

 

1. Definitions.
As used in this Agreement, the following terms have the respective meanings set forth below:

 

“Aggregate
Exercise Price” means an amount equal to the product of (a) the number of Warrant Shares in respect of which such Warrant is
then being exercised pursuant to Section 4 hereof, multiplied by (b) the Exercise Price.

 

“Board”
means the board of directors of the Company.

 

“Business
Day” means any day, except a Saturday, Sunday or legal holiday, on which banking institutions in the city of Omaha, Nebraska
are authorized or obligated by law or executive order to close.

 

“Common
Stock” means (i) the common stock, of the Company, $0.001 par value per share, as authorized as of the date hereof and (ii)
any capital stock into which the securities described in subsection (i) shall have been converted, exchanged or reclassified following
the date hereof.

 

     

     

    

 

“Exercise
Date” means, for any given exercise of each Warrant, the date on which the conditions to such exercise as set forth in Section
4 shall have been satisfied at or prior to 5:00 p.m. (Central) on a Business Day, including, without limitation, the receipt by the Company
of the Notice of Exercise.

 

“Fair
Market Value” means, if the Company’s Common Stock is then traded or quoted on a nationally recognized securities exchange,
inter-dealer quotation system or over-the- counter market (a “Trading Market”), the fair market value of a share of
Common Stock shall be the closing price or last sale price of a share of the Common Stock reported for the Business Day immediately before
the date on which Holder delivers its Notice of Exercise to the Company. If the Company’s Common Stock is not traded in a Trading
Market, the Board of the Company shall determine the fair market value of a share of Common Stock in its reasonable good faith judgment.

 

“Person”
means any individual, sole proprietorship, partnership, limited liability company, corporation, joint venture, trust, incorporated organization
or government or department or agency thereof.

 

“Warrant
Shares” means the shares of Common Stock of the Company then purchasable upon exercise of each Warrant in accordance with the
terms of this Agreement.

 

2.
Warrants. The Company hereby agrees to issue the following warrants to Holder:

 

(a) The
Company shall issue, on the Effective Date, a warrant (the “Initial Warrant”) to Holder which certifies that Holder
is entitled to purchase from the Company One Million (1,000,000) duly authorized, validly issued, fully paid and nonassessable shares
of Common Stock at a purchase price per share of Zero and 25/100 Dollars ($0.25) (the “Exercise Price”), subject to
the terms and conditions of this Agreement.

 

(b) Provided
the Consulting Agreement is still in force and effect and subject to the terms and conditions of this Agreement, the Company shall issue,
on each anniversary of the Effective Date for three (3) consecutive years, an additional warrant (each, an “Additional Warrant”,
and along with the Initial Warrant, each a “Warrant” and collectively the “Warrants”) to Holder
which certifies that Holder is entitled to purchase from the Company Additional Shares of Common Stock that are duly authorized, validly
issued, fully paid and nonassessable at a purchase price per share of the Exercise Price. For purpose of this Agreement, “Additional
Shares” means an amount of shares equal to the product of (i) Two Hundred and Fifty Thousand (250,000) multiplied by (ii) (x)
the number of Principals (as defined in the Consulting Agreement) performing Services on behalf of the Consultant in a meaningful manner
in the reasonable discretion of Company as of such anniversary plus (y) the number of Principals not performing Services on behalf of
the Consultant due to death or being deemed Disabled as of such anniversary. Notwithstanding anything herein to the contrary, the maximum
amount of Additional Shares per Additional Warrant shall be One Million (1,000,000) shares. By way of example, if, on the third (3rd)
anniversary of the Effective Date, two (2) Principals are performing Services on behalf of the Consultant and one (1) Principal is not
performing Services on behalf of the Consultant due to either being deemed Disabled or having died, the Additional Warrant issued by
the Company to Holder shall be for Seven Hundred Fifty Thousand (750,000) shares of Common Stock.

 

    	 	2	 

     

    

 

(c)
For purposes of this Agreement, “Disabled” means, in regards to a Principal, physically and/or mentally unable to
perform all or substantially all of such Principal’s usual and customary duties as a Principal under the Consulting Agreement
currently and for the foreseeable future and such inability has continued for at least six (6) consecutive months. The determination
of whether a Principal is “Disabled” under the foregoing definition shall be made by one or more physicians selected for
that purpose by the Company.

 

3. Term
of Warrant. Subject to the terms and conditions hereof, at any time or from time to time after each respective Warrant is issued
and prior to 5:00 p.m. (Central) on the seventh (7th) anniversary of the Effective Date or, if such day is not a Business Day, on the
next preceding Business Day (the “Exercise Period”), the Holder may exercise each Warrant for all but not less than
all of the Warrant Shares purchasable thereunder (subject to adjustment as provided herein).

 

 4. Exercise of Warrant.

 

(a) Exercise
Procedure. Each Warrant may be exercised by the Holder delivering the Company a duly executed Notice of Exercise form, attached hereto
as Exhibit A (the “Notice of Exercise”), from time to time on any Business Day during the Exercise Period,
for all but not less than all of the Warrant Shares purchasable thereunder, and payment to the Company of the Aggregate Exercise Price
in accordance with Section 4(b).

 

(b) Payment
of the Aggregate Exercise Price. Payment of the Aggregate Exercise Price shall be made by instructing the Company to issue Warrant
Shares then issuable upon exercise of each Warrant on a net basis such that, without payment of any cash consideration or other immediately
available funds, the Holder shall surrender each Warrant in exchange for the number of Warrant Shares as is computed using the following
formula:

 

X
= Y(A - B) ÷ A

 

Where:

 

X
= the number of Warrant Shares to be issued to the Holder.

 

Y
= the total number of Warrant Shares purchasable under such Warrant.

 

A
= the Fair Market Value of one Warrant Share as of the applicable Exercise Date.

 

B = the Exercise Price.

 

(c) Fractional
Shares. The Company shall not issue a fractional Warrant Share upon exercise of any Warrant. In the event of withholding of Warrant
Shares where the number of shares whose value is equal to the Aggregate Exercise Price is not a whole number, the number of shares withheld
by the Company shall be rounded up to the nearest whole share and the Company shall make a cash payment to the Holder (by delivery of
a certified or official bank check or by wire transfer of immediately available funds) based on the incremental fraction of a share being
so withheld by the Company in an amount equal to the product of (i) such incremental fraction of a share being so withheld multiplied
by (ii) the Fair Market Value per Warrant Share as of the Exercise Date.

 

    	 	3	 

     

    

 

(d) Delivery
of Stock Certificates. Within a reasonable time after each Warrant is exercised hereunder, the Company shall execute (or cause
to be executed) and deliver (or cause to be delivered) to the Holder a certificate or certificates representing the Warrant Shares
issued upon such exercise, together with cash in lieu of any fraction of a share, as provided in Section 4(c). The stock certificate
or certificates so delivered shall be, to the extent possible, in such denomination or denominations as the exercising Holder shall
reasonably request in the Notice of Exercise and shall be registered in the name of the Holder or, subject to compliance with
Section 6 below, such other Person’s name as shall be designated in the Notice of Exercise. Each Warrant shall be deemed to
have been exercised and such certificate or certificates of Warrant Shares shall be deemed to have been issued, and the Holder or
any other Person so designated to be named therein shall be deemed to have become a holder of record of such Warrant Shares for all
purposes, as of the Exercise Date.

 

(e) Company’s
Representations and Covenants. The Company hereby represents, covenants and agrees:

 

 (i) Each Warrant is, upon issuance, duly authorized and validly issued.

 

(ii) All
Warrant Shares issuable upon the exercise of each Warrant pursuant to the terms hereof shall be, upon issuance, and the Company shall
take all such actions as may be reasonably necessary or appropriate in order that such Warrant Shares are, validly issued, fully paid
and non-assessable, free and clear of all taxes, liens and charges except for restrictions imposed by applicable federal and state securities
laws.

 

(iii) The
Company shall take commercially reasonable actions to help cause the Warrant Shares to be issued without violation by the Company of
any applicable law or governmental regulation or any requirements of any domestic securities exchange upon which shares of Common Stock
or other securities constituting Warrant Shares may be listed at the time of such exercise.

 

(iv) The
Company shall pay all expenses in connection with, and all taxes and other governmental charges that may be imposed with respect to,
the issuance or delivery of Warrant Shares upon exercise of each Warrant; provided, that the Company shall not be required to pay any
tax or governmental charge that may be imposed with respect to any applicable withholding or the issuance or delivery of the Warrant
Shares to any Person other than the Holder, and no such issuance or delivery shall be made unless and until the Person requesting such
issuance has paid to the Company the amount of any such tax, or has established to the satisfaction of the Company that such tax has
been paid.

 

(f) Conditional
Exercise. Notwithstanding any other provision hereof and subject to the Exercise Period, if an exercise of any Warrant is to be made
in connection with a public offering or a sale of the Company (pursuant to a merger, sale of stock, or otherwise), such exercise may
at the election of the Holder be conditioned upon the consummation of such transaction, in which case such exercise shall not be deemed
to be effective until immediately prior to the consummation of such transaction.

 

(g) Reservation
of Shares. During the Exercise Period, the Company shall at all times reserve and keep available out of its authorized but
unissued Common Stock or other securities constituting Warrant Shares, solely for the purpose of issuance upon the exercise of the
Warrants, the maximum number of Warrant Shares issuable upon the exercise of the Warrants, and the par value per Warrant Share shall
at all times be less than or equal to the applicable Exercise Price. The Company shall not increase the par value of any Warrant
Shares receivable upon the exercise of any Warrant above the Exercise Price then in effect, and shall take all such actions as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common
Stock upon the exercise of this Warrant.

 

    	 	4	 

     

    

 

 5. Adjustment to Number of Warrant Shares.

 

(a) Stock
Dividends and Split-Ups. If after the Effective Date, and subject to the provisions of Section 5(c), the number of outstanding shares
of Common Stock is increased by a stock dividend payable in shares of Common Stock, or by a split-up of shares of Common Stock, or other
similar event, then, on the effective date of such stock dividend, split-up or similar event, the number of shares of Common Stock issuable
upon exercise of each Warrant shall be increased in proportion to such increase in outstanding shares of Common Stock upon the Holder’s
delivery of the Notice of Exercise.

 

(b) Aggregation
of Shares. If after the Effective Date, and subject to the provisions of Section 5(c), the number of outstanding shares of Common
Stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of Common Stock or other similar
event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar event, the number
of shares of Common Stock issuable upon exercise of each Warrant shall be decreased in proportion to such decrease in outstanding shares
of Common Stock upon the Holder’s delivery of the Notice of Exercise.

 

(c) Adjustments
in Exercise Price. Whenever the number of shares of Common Stock purchasable upon the exercise of the Warrants is adjusted, as provided
in Sections 6.1(a) and (b), the Exercise Price shall be adjusted (to the nearest cent) by multiplying such Exercise Price immediately
prior to such adjustment by a fraction (i) the numerator of which shall be the number of shares of Common Stock purchasable upon the
exercise of the Warrant immediately prior to such adjustment, and (ii) the denominator of which shall be the number of shares of Common
Stock so purchasable immediately thereafter.

 

(d) Reorganization,
Reclassification, Consolidation or Merger. In the event of any (i) capital reorganization of the Company, (ii) reclassification
of the stock of the Company (other than a change in par value or as a result of a stock dividend or split-up, aggregation or
combination of shares), (iii) consolidation or merger of the Company with or into another Person, (iv) sale of all or substantially
all of the Company’s assets to another Person or (v) other similar transaction (other than any such transaction covered by
Sections 6.1(a) and (b)), in each case which entitles the holders of Common Stock to receive (either directly or upon subsequent
liquidation) stock, securities or assets with respect to or in exchange for Common Stock, each Warrant shall, immediately after such
reorganization, reclassification, consolidation, merger, sale or similar transaction, remain outstanding and shall thereafter, in
lieu of or in addition to (as the case may be) the number of Warrant Shares then exercisable under each Warrant, be exercisable for
the kind and number of shares of stock or other securities or assets of the Company or of the successor Person resulting from such
transaction to which the Holder would have been entitled upon such reorganization, reclassification, consolidation, merger, sale or
similar transaction if the Holder had exercised such Warrant immediately prior to the time of such reorganization, reclassification,
consolidation, merger, sale or similar transaction and acquired the applicable number of Warrant Shares then issuable hereunder as a
result of such exercise (without taking into account any limitations or restrictions on the exercisability of this Warrant); and, in
such case, appropriate adjustment shall be made with respect to the Holder’s rights under this Agreement to insure that the
provisions of this Section 5 shall thereafter be applicable, as nearly as possible, to each Warrant in relation to any shares of
stock, securities or assets thereafter acquirable upon exercise of such Warrant. The provisions of this Section 5(d) shall similarly
apply to successive reorganizations, reclassifications, consolidations, mergers, sales or similar transactions.

 

    	 	5	 

     

    

 

(e) Notice
of Adjustment. As promptly as reasonably practicable following any adjustment of the number of Warrant Shares pursuant to the provisions
of this Section 5, the Company shall furnish to the Holder notice setting forth in reasonable detail such adjustment and the facts upon
which it is based.

 

(f) Notice
of Corporate Events. If the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect
of its Common Stock, (ii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, or (iii) authorizes
any capital reorganization of the Company, any reclassification of the Common Stock of the Company, any consolidation or merger of the
Company with or into another Person, or sale of all or substantially all of the Company’s assets to another Person, then the Company
shall deliver to each Holder a notice describing the material terms and conditions of such dividend or transaction. Notwithstanding anything
to the contrary in this Section 5(f), the failure to deliver any notice under this Section 5(f) or any defect therein shall
not affect the validity of the corporate action required to be described in such notice.

 

 6. Registration and Transfer.

 

(a) Registration.
Each Warrant shall be issued in registered form only. The Company shall maintain books and records (the “Records”)
for the registration of original issuance, the adjustments contemplated herein, the transfer of any Warrant and any other information
relevant to the terms and conditions of this Agreement. The Company may deem and treat the Person in whose name the Warrant is registered
on such register as the Holder thereof for all purposes, and the Company shall not be affected by any notice to the contrary, except
any transfer of the Warrant effected in accordance with the provisions of this Agreement.

 

(b) Transfer
of Warrant. Subject to the provisions of this Agreement and compliance with applicable securities laws, each Warrant and all rights
hereunder are transferable, in whole or in part, by the Holder without charge to the Holder, upon (i) delivery of written notice to the
Company stating the name, address and taxpayer identification number, the Warrant being transferred and such other information describing
the transfer (including that the transferee has agreed to be bound by the terms and conditions of this Agreement), together with funds
sufficient to pay any transfer taxes incurred with the making of such transfer and (ii) delivery of an opinion of counsel reasonably
satisfactory to the Company that the transfer of the Warrant will be in compliance with applicable securities laws. Upon such delivery,
Company shall update the Records to reflect the transferee as holder of the transferred Warrant.

 

7. Holder
Not Deemed a Stockholder; Limitations on Liability. Except as otherwise specifically provided herein (including Section 5(f)),
prior to the issuance to the Holder of the Warrant Shares to which the Holder is then entitled to receive upon the due exercise of
each Warrant, the Holder shall not be entitled to vote or receive dividends or be deemed the holder of shares of capital stock of
the Company for any purpose, nor shall anything contained in this Agreement be construed to confer upon the Holder, as such, any of
the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any
reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of
meetings, receive dividends or subscription rights, or otherwise. In addition, nothing contained in this Agreement shall be
construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of each Warrant or otherwise) or as a
stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.

 

    	 	6	 

     

    

 

8. Representations
of the Holder. The Holder hereby represents and warrants to the Company as follows:

 

(a) The
Holder is an “accredited investor” as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933, as
amended (the “Securities Act”). The Holder is acquiring each Warrant and the Warrant Shares to be issued upon exercise
thereof for investment for its own account and not with a view towards, or for resale in connection with, the public sale or distribution
of any Warrant or the Warrant Shares, except pursuant to sales registered or exempted under the Securities Act.

 

(b) The
Holder understands and acknowledges that each Warrant and the Warrant Shares to be issued upon exercise thereof are “restricted
securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving
a public offering and that, under such laws and applicable regulations, such securities may be resold without registration under the
Securities Act only in certain limited circumstances. In addition, the Holder represents that it is familiar with Rule 144 under the
Securities Act, as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act.

 

(c) The
Holder acknowledges that it can bear the economic and financial risk of its investment for an indefinite period, and has such knowledge
and experience in financial or business matters that it is capable of evaluating the merits and risks of each Warrant and the Warrant
Shares to be issued upon exercise thereof. The Holder has had an opportunity to ask questions and receive answers from the Company regarding
the business, properties, prospects and financial condition of the Company.

 

9. Notices.
All notices, requests, and other communications hereunder shall be deemed to be duly given if sent by U.S. mail, postage prepaid, addressed
to the other party at the address as set forth herein below:

 

To
the Company:

 

Biosecurity
Technology, Inc.

3821 S. 148th Street

Omaha,
NE 68130

Attn: Dan Lynn

 

With
a copy to:

 

Dvorak
Law Group, LLC

9500 W. Dodge Rd., Ste. 100

Omaha,
NE 68114

Attn: David R. Mayer

 

To
the Consultant:

 

Global
Food Innovations, LLC

1762 FM 2060

Abernathy,
TX 79311

Attn: Mark Miller

 

    	 	7	 

     

    

 

Either
party may change the address to which notices for it shall be addressed by providing notice of such change to the other party in the
manner set forth in this Section.

 

10. Entire
Agreement. This Agreement constitutes the sole and entire agreement of the parties to this Agreement with respect to the subject
matter contained herein, and supersedes all prior and contemporaneous understandings and agreements, both written and oral, with respect
to such subject matter.

 

11. Successors
and Assigns; No Third-Party Beneficiaries. This Agreement is for the sole benefit of and binding upon the Company and the Holder
and their respective successors and, in the case of the Holder, permitted assigns and nothing herein, express or implied, is intended
to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever, under or by reason
of this Agreement.

 

12. Headings.
The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.

 

13. Amendment
and Modification; Waiver. Except as otherwise provided herein, this Agreement may only be amended, modified or supplemented by an
agreement in writing signed by each party hereto. No waiver by the Company or the Holder of any of the provisions hereof shall be effective
unless explicitly set forth in writing and signed by the party so waiving. No waiver by any party shall operate or be construed as a
waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different
character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any rights, remedy, power
or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise
of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right,
remedy, power or privilege.

 

14. Severability.
If any term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or
unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision
in any other jurisdiction.

 

15. Choice
of Law, Jurisdiction and Venue. This Agreement shall be governed by, construed and enforced in accordance with the laws of the State
of Nebraska without giving effect to any conflict of laws principles that would cause the laws of any other jurisdiction to apply. The
parties agree that the state or federal courts located in Douglas County, Nebraska shall have exclusive venue of any dispute and will
have jurisdiction over all parties.

 

16. Counterparts.
This Agreement may be executed in multiple counterparts and by electronic signature, each of which shall be deemed an original and all
of which together shall constitute one instrument.

 

[Rest
of Page Intentionally Left Blank; Signature Page Follows.]

 

    	 	8	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.

 

	 	COMPANY:
	 	 
	 	Biosecurity Technology, Inc.
	 	 
	 	By:	/s/ Dan Lynn
	 	Name:	Dan Lynn
	 	Title:	CEO
	 	 
	 	HOLDER:
	 	 
	 	Global Food Innovations, LLC
	 	 
	 	By:	/s/ Mark Miller
	 	Name:	Mark Miller
	 	Title:	Manager

 

 

Purchase Warrant Agreement 

Signature Page

 

     

     

    

 

EXHIBIT
A

 

Notice
of Exercise

 

Exercise
Date:__________________________

To: Biosecurity Technology, Inc.

 

The
undersigned, subject to the provisions set forth in that certain Purchase Warrant Agreement, dated April 28, 2021 (the “Agreement”),
hereby irrevocably elects to purchase the number of shares of Common Stock of Biosecurity Technology, Inc., a Nevada corporation (the
“Company”), subject to the applicable Warrant, each as set forth below. The undersigned hereby agrees to pay the Aggregate
Exercise Price for such shares of Common Stock in accordance with the terms and conditions of the Agreement. The undersigned reaffirms
the representations and warranties set forth in Section 8 of the Agreement. Capitalized terms used herein and not otherwise defined shall
have the meaning ascribed to them in the Agreement.

 

Date of Issuance of Warrant:                                              

 

Number of Shares of Common Stock:                                         

 

The
undersigned requests that certificates for the shares of Common Stock be issued in the name of:

 

	Name:	 	 
	Address:	 	 
	SSN / Tax ID:	                         	 
	Number of Shares:	 	 

 

	 	HOLDER:
	 	 
	 	 
	 	By:	 
	 	Name:	 
	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]